摘要
目的:探讨血清糖类抗原199(CA199)、恶性肿瘤特异性生长因子(TSGF)水平与非小细胞肺癌(NSCLC)患者预后生存的关系。方法:选择2019年3月至2021年3月本院收治的118例NSCLC患者,采用酶联免疫吸附法检测患者入院及3个周期治疗结束后血清CA199、TSGF水平。采用受试者工作特征(ROC)曲线评估血清CA199、TSGF水平对NSCLC患者预后的预测价值;Kaplan-Meier生存曲线分析血清CA199、TSGF表达水平与NSCLC患者预后的关系。结果:治疗后所有患者血清CA199、TSGF水平较治疗前均下降,治疗前后死亡组血清CA199、TSGF水平均高于生存组(P<0.05)。Kaplan-Meier生存曲线显示,根据CA199、TSGF表达水平的中位数进行分组,伴有高表达CA199(≥68.22 U·mL^(-1))患者3年生存率(53.33%)低于低表达CA199(<68.22 U·mL^(-1))患者(67.24%)(χ^(2)=5.827,P=0.016);高表达TSGF(≥155.68 U·mL^(-1))患者3年生存率(52.54%)低于低表达TSGF(<155.68 U·mL^(-1))患者(67.80%)(χ^(2)=6.621,P=0.010)。CA199、TSGF联合预测NSCLC患者预后的AUC为0.867(95%CI:0.792~0.922),显著大于CA199单独预测的AUC(Z=2.402,P=0.016)及TSGF单独预测的AUC(Z=2.235,P=0.025)。结论:血清CA199、TSGF水平与贝伐珠单抗联合紫杉醇、顺铂辅助化疗方案治疗后NSCLC患者预后生存相关。
Objective:To explore the relationship between serum carbohydrate antigen 199(CA199),tumor-specific growth factor(TSGF)levels with the prognostic survival of non-small cell lung cancer(NSCLC)patients treated with bevacizumab combined with TP adjuvant chemotherapy.Methods:From March 2019 to March 2021,118 NSCLC patients who visited our hospital were enrolled.Using enzyme-linked immunosorbent assay to detect serum CA199 and TSGF levels in patients after admission and three cycles of treatment.ROC curve was applied to evaluate the predictive value of serum CA199 and TSGF levels for the prognosis of NSCLC patients.Kaplan-Meier survival curve was used to analyze the relationship between serum CA199,TSGF expression levels with the prognosis of NSCLC.Results:After treatment,the serum levels of CA199 and TSGF in both groups decreased compared to before treatment,the serum levels of CA199 and TSGF in the death group were higher than those in the survival group before and after treatment(P<0.05).Kaplan-Meier survival curves showed that according to the median expression levels of CA199 and TSGF,patients with high CA199 expression(≥68.22 U·mL^(-1))had a 3-year survival rate(53.33%)lower than those with low CA199 expression(<68.22 U·mL^(-1))(67.24%)(χ^(2)=5.827,P=0.016);The 3-year survival rate(52.54%)of patients with high expression of TSGF(≥155.68 U·mL^(-1))was lower than that of patients with low expression of TSGF(<155.68 U·mL^(-1))(67.80%)(χ^(2)=6.621,P=0.010).The AUC predicted by the combination of CA199 and TSGF for the prognosis of NSCLC was 0.867(95%CI:0.792-0.922),obviously higher than the AUC predicted by CA199 alone(Z=2.402,P=0.016)and TSGF alone(Z=2.235,P=0.025).Conclusion:Serum levels of CA199 and TSGF are associated with the prognostic survival of NSCLC patients treated with bevacizumab combined with TP adjuvant chemotherapy.
作者
卢秀明
柴宝英
曹颖祺
刘鑫
杨琳
LU Xiuming;CHAI Baoying;CAO Yingqi;LIU Xin;YANG Lin(Department of Oncology,the Second Hospital of Qinhuangdao,Qinhuangdao 066600,China)
出处
《东南大学学报(医学版)》
2025年第4期569-574,共6页
Journal of Southeast University(Medical Science Edition)
基金
河北省医学科学研究课题计划项目(20231895)。
